Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Bariatrics
Description:
Body Mass Index, or BMI, is a simple calculation using your height and weight to estimate body fat. While it doesn’t measure fat directly, it gives a useful indication of whether you’re in a healthy range. A BMI between 18.5 and 24.9 is considered normal, while values outside this range can signal potential health risks. For example, a high BMI is linked to increased chances of heart disease, diabetes, and certain cancers. On the other hand, a low BMI may suggest malnutrition or other underlying issues. Remember, BMI is just one tool—other factors like muscle mass, age, and genetics also play a role. Always consult a healthcare professional for a complete picture of your health.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge